The 2026 SelectUSA Investment Summit marked a milestone in U.S.– India economic ties, as Indian industry leaders announced $20.5 billion in new investments across the United States. The commitments highlight India’s growing role as a strategic partner in the American economy, spanning pharmaceuticals, advanced manufacturing, energy infrastructure, and emerging technologies. Officials say the projects are expected to create thousands of jobs, strengthen supply chains, and expand domestic production capacity.
Pharmaceutical Sector Leads the Charge
The pharmaceutical industry accounted for the lion’s share of the investment, with Indian companies pledging more than $19.1 billion. At the center of this wave is Sun Pharmaceutical Industries Ltd., which unveiled plans for an $11.75 billion acquisition of New Jersey-based Organon & Co.
Other major players joining the effort include Aurobindo Pharma Ltd, Biocon Group, Cipla Limited, Dr. Reddy’s Laboratories Ltd, Glenmark Pharmaceuticals Ltd, Granules India Ltd, Jubilant Group, Lupin Limited, Piramal Pharma Ltd, and Zydus Lifesciences Limited.
Executives emphasized that the investments will fund manufacturing expansions, new greenfield facilities, and increased research and development. Industry leaders say these moves will help expand the supply of essential medicines, address ongoing drug shortages, and reinforce the resilience of the U.S. healthcare supply chain.
Strengthening Economic Ties
The announcements underscore a broader trend of Indian companies deepening their footprint in the United States. Analysts note that the scale of investment reflects confidence in the U.S. market and a commitment to building long-term partnerships that benefit both economies.
